Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLC

Robert C. Doebele, MD, PhD
Published: Monday, Oct 30, 2017



Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non–small cell lung cancer (NSCLC).

Crizotinib (Xalkori), the current standard of care, does not have good central nervous system (CNS) penetration; therefore, CNS metastases cannot be well controlled. However, entrectinib is a very CNS-penetrant brain metastases-active compound, says Doebele.

Entrectinib may allow for better upfront control of existing brain metastases, and may prevent the development of brain metastases in the future.


Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non–small cell lung cancer (NSCLC).

Crizotinib (Xalkori), the current standard of care, does not have good central nervous system (CNS) penetration; therefore, CNS metastases cannot be well controlled. However, entrectinib is a very CNS-penetrant brain metastases-active compound, says Doebele.

Entrectinib may allow for better upfront control of existing brain metastases, and may prevent the development of brain metastases in the future.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x